Tzelves Lazaros, Geraghty Robert, Lombardo Riccardo, Davis Niall F, Petřík Ales, Neisius Andreas, Gambaro Giovanni, Türk Christian, Thomas Kay, Somani Bhaskar, Skolarikos Andreas
Department of Urology, Sismanogleio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK.
Eur Urol Focus. 2023 Jan;9(1):188-198. doi: 10.1016/j.euf.2022.06.016. Epub 2022 Jul 16.
No algorithm exists for structured follow-up of urolithiasis patients.
To provide a discharge time point during follow-up of urolithiasis patients after treatment.
We performed a systematic review of PubMed/Medline, EMBASE, Cochrane Library, clinicaltrials.gov, and reference lists according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Fifty studies were eligible.
From a pooled analysis of 5467 stone-free patients, we estimated that for a safety margin of 80% for remaining stone free, patients should be followed up using imaging, for at least 2 yr (radiopaque stones) or 3 yr (radiolucent stones) before being discharged. Patients should be discharged after 5 yr of no recurrence with a safety margin of 90%. Regarding residual disease, patients with fragments ≤4 mm could be offered surveillance up to 4 yr since intervention rates range between 17% and 29%, disease progression between 9% and 34%, and spontaneous passage between 21% and 34% at 49 mo. Patients with larger residual fragments should be offered further definitive intervention since intervention rates are high (24-100%). Insufficient data exist for high-risk patients, but the current literature dictates that patients who are adherent to targeted medical treatment seem to experience less stone growth or regrowth of residual fragments, and may be discharged after 36-48 mo of nonprogressive disease on imaging.
This systematic review and meta-analysis indicates that stone-free patients with radiopaque or radiolucent stones should be followed up to 2 or 3 yr, respectively. In patients with residual fragments ≤4 mm, surveillance or intervention can be advised according to patient preferences and characteristics, while for those with larger residual fragments, reintervention should be scheduled.
Here, we review the literature regarding follow-up of urolithiasis patients. Patients who have no stones after treatment should be seen up to 2-3 yr, those with large fragments should be reoperated, and those with small fragments could be offered surveillance with imaging.
目前尚无针对尿石症患者进行结构化随访的算法。
确定尿石症患者治疗后随访期间的出院时间点。
我们根据系统评价和Meta分析的首选报告项目声明,对PubMed/Medline、EMBASE、Cochrane图书馆、clinicaltrials.gov以及参考文献列表进行了系统评价。共有50项研究符合条件。
通过对5467例结石清除患者的汇总分析,我们估计,为确保80%的无结石安全边际,不透射线结石患者在出院前应至少接受2年的影像学随访,透光结石患者则应至少接受3年的影像学随访。患者在无复发5年后,且安全边际达到90%时可出院。对于残留疾病,残留碎片≤4 mm的患者可进行长达4年的监测,因为在49个月时,干预率在17%至29%之间,疾病进展率在9%至34%之间,自然排出率在21%至34%之间。残留碎片较大的患者应接受进一步的确定性干预,因为干预率很高(24% - 100%)。关于高危患者的数据不足,但目前的文献表明,坚持针对性药物治疗的患者结石生长或残留碎片再生长的情况似乎较少,在影像学检查显示疾病无进展36 - 48个月后可能出院。
本系统评价和Meta分析表明,不透射线或透光结石的结石清除患者应分别随访2年或3年。对于残留碎片≤4 mm的患者,可根据患者偏好和特征建议进行监测或干预,而对于残留碎片较大的患者,则应安排再次干预。
在此,我们回顾了有关尿石症患者随访的文献。治疗后无结石的患者应随访2 - 3年,碎片较大的患者应再次手术,碎片较小的患者可进行影像学监测。